Scarica l'app Stockscreener
2.05
3.99%
-0.08
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NMRA Giù?
Forum
Previsione
Precedente Chiudi:
$2.13
Aprire:
$2.14
Volume 24 ore:
320.29K
Relative Volume:
0.15
Capitalizzazione di mercato:
$348.37M
Reddito:
-
Utile/perdita netta:
$-274.18M
Rapporto P/E:
-0.8088
EPS:
-2.5346
Flusso di cassa netto:
$-198.33M
1 W Prestazione:
+4.87%
1M Prestazione:
+14.89%
6M Prestazione:
-10.31%
1 anno Prestazione:
+1.74%
Intervallo 1D:
$2.02
$2.18
Intervallo di 1 settimana:
$1.9202
$2.20
Portata 52W:
$0.611
$3.25
Neumora Therapeutics Inc Stock (NMRA) Company Profile
Nome
Neumora Therapeutics Inc
Settore
Industria
Telefono
(857) 760-0900
Indirizzo
260 ARSENAL PLACE, SUITE 1, WATERTOWN
Confronta NMRA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
2.05 | 361.97M | 0 | -274.18M | -198.33M | -2.5346 |
|
VRTX
Vertex Pharmaceuticals Inc
|
478.52 | 120.31B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.55 | 81.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
848.66 | 53.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
351.02 | 46.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
347.18 | 37.20B | 4.98B | 69.59M | 525.67M | 0.5197 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-12 | Iniziato | Leerink Partners | Outperform |
| 2025-12-01 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-10-27 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2025-09-16 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-04-02 | Downgrade | BofA Securities | Buy → Underperform |
| 2025-03-10 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-03-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-03-07 | Downgrade | Stifel | Buy → Hold |
| 2025-01-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-05 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-10-01 | Iniziato | H.C. Wainwright | Buy |
| 2024-07-22 | Iniziato | Needham | Buy |
| 2024-07-08 | Iniziato | Mizuho | Outperform |
| 2023-12-12 | Iniziato | Deutsche Bank | Hold |
| 2023-10-10 | Iniziato | BofA Securities | Buy |
| 2023-10-10 | Iniziato | Guggenheim | Buy |
| 2023-10-10 | Iniziato | JP Morgan | Overweight |
| 2023-10-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-10-10 | Iniziato | Stifel | Buy |
| 2023-10-10 | Iniziato | William Blair | Outperform |
Mostra tutto
Neumora Therapeutics Inc Borsa (NMRA) Ultime notizie
FY2030 Earnings Estimate for NMRA Issued By HC Wainwright - MarketBeat
Stop Loss: Can QMMM Holdings Limited navigate macro headwindsQuarterly Market Review & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Investment Review: What makes SZZLU stock attractive todayInflation Watch & Weekly High Return Forecasts - baoquankhu1.vn
NMRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Targets Report: Can AZEK continue delivering strong returnsQuarterly Profit Report & AI Based Trade Execution Alerts - baoquankhu1.vn
Volume Report: Is Neumora Therapeutics Inc showing insider buying2025 Fundamental Recap & Weekly Return Optimization Alerts - baoquankhu1.vn
Earnings Beat: Should I hold or sell SPCE nowMarket Weekly Review & Fast Gain Stock Trading Tips - baoquankhu1.vn
RSI Check: Is Neumora Therapeutics Inc benefiting from innovation trends2025 Short Interest & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Aug Wrap: Is Castle Biosciences Inc vulnerable to short sellersVolume Spike & Breakout Confirmation Alerts - baoquankhu1.vn
Why Neumora Therapeutics Inc stock appeals to analystsProduct Launch & Smart Allocation Stock Reports - Bộ Nội Vụ
Neumora Therapeutics (NASDAQ:NMRA) Upgraded at Leerink Partnrs - MarketBeat
Leerink Partners Initiates Coverage of Neumora Therapeutics (NMRA) with Outperform Recommendation - Nasdaq
Leerink Partners Begins Coverage on Neumora Therapeutics (NASDAQ:NMRA) - MarketBeat
Leerink Initiates Neumora Therapeutics at Outperform With $8 Price Target - marketscreener.com
Neumora outlines 2026 neuroscience pipeline and obesity plans - TipRanks
Neumora Therapeutics, Inc. Presents at J.P. Morgan Healthcare Conference - TradingView — Track All Markets
Diversified CNS Pipeline and NLRP3 Opportunity Drive Upside in Neumora: Justifying an Outperform/Buy Rating - TipRanks
Leerink Partners initiates coverage on Neumora stock with Outperform rating By Investing.com - Investing.com Canada
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Is Neumora Therapeutics Inc. stock a defensive play in 2025Gap Down & Advanced Technical Analysis Signals - Улправда
Published on: 2026-01-12 18:50:31 - ulpravda.ru
Neumora Therapeutics touts Phase 1B NMRA-511 gains in Alzheimer’s agitation, eyes higher doses - MarketBeat
Neumora gains after early-stage trial results for Alzheimer’s product - MSN
Trend Review: What hedge fund activity signals for Neumora Therapeutics Inc. stockJuly 2025 Sector Moves & Weekly Chart Analysis and Guides - Улправда
Can Neumora Therapeutics Inc. stock beat market expectations this quarterVolume Analysis Techniques & Turn Data into Profits With Our Strategies - Улправда
Mizuho reiterates Outperform rating on Neumora Therapeutics stock By Investing.com - Investing.com Canada
Analysts Are Bullish on These Healthcare Stocks: Fortrea Holdings Inc. (FTRE), DENTSPLY SIRONA (XRAY) - The Globe and Mail
Neumora outlines 2026 pipeline milestones for neuroscience programs By Investing.com - Investing.com Nigeria
Positive Risk-Reward on Neumora as NMRA-511 Emerges as a Differentiated Therapy for Alzheimer’s Agitation, Supporting Buy Rating and $18 Target - TipRanks
Mizuho raises Neumora Therapeutics stock price target on positive trial data - Investing.com Canada
Neumora shares climb after encouraging Phase 1b results for Alzheimer’s agitation therapy - MSN
Why Is Neumora Therapeutics Stock Gaining Monday?Neumora Therapeutics (NASDAQ:NMRA) - Benzinga
Neumora's Alzheimer's Agitation Drug Shows Early Promise - Sahm
Neumora stock rises after positive Phase 1b data for Alzheimer’s agitation drug - Investing.com Nigeria
Neumora stock rises after positive Phase 1b data for Alzheimer’s agitation drug By Investing.com - Investing.com South Africa
NMRA Surges On Clinically Meaningful Results In Phase 1 Alzheimer's Disease Agitation Study - Nasdaq
Neumora outlines 2026 pipeline milestones for neuroscience programs - Investing.com
Neumora posts trial results for Alzheimer’s drug (NMRA:NASDAQ) - Seeking Alpha
Neumora Therapeutics Reports Encouraging Phase 1b Data For NMRA-511 In Alzheimer's Disease Agitation - Nasdaq
Neumora reports promising Phase 1b results in Alzheimer’s agitation - TipRanks
Neumora Therapeutics Announces Positive Phase 1b Study Results for NMRA-511 - TradingView — Track All Markets
Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones - The Manila Times
Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer’s Disease Agitation - The Manila Times
New Alzheimer’s treatment candidate eases agitation in early study - Stock Titan
10 Best New Penny Stocks to Invest In - Insider Monkey
RBC Sees Upside Potential in Neumora Therapeutics (NMRA) - Finviz
What analysts say about Neumora Therapeutics Inc stockMid Cap Growth Trends & Free Superior Trading Gains - earlytimes.in
Momentum Shift: Will Neumora Therapeutics Inc. stock benefit from AI adoptionNew Guidance & Consistent Income Trade Recommendations - moha.gov.vn
Cash Runway Looks Solid, But Is Neumora's Pipeline Ready To Deliver? - RTTNews
Is Neumora Therapeutics Inc. stock resilient to inflation2025 Volatility Report & Fast Gaining Stock Reports - Улправда
Neumora Therapeutics Inc Azioni (NMRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.00%
2.97%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):